Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025
Psyence BioMed (NASDAQ: PBM) secured a sustainable supply of pharmaceutical-grade ibogaine through PsyLabs, receiving an initial 50 kg shipment of high-potency iboga bark for processing. PBM shares rose 21.5% to $3.39 in pre-market trading Thursday, after being named among top healthcare movers.
